Gilead, Bristol-Myers Squibb to Work Together to Develop Single Daily Combination Antiretroviral Drug
December 21, 2004
Pharmaceutical companies Gilead and Bristol-Myers Squibb on Monday announced a collaboration to develop the first single daily combination antiretroviral drug to treat HIV/AIDS patients, the AP/Houston Chronicle reports. The combination pill could be approved and marketed by late 2006 because the three individual drugs already are FDA approved, according to David Rosen, a Bristol-Myers Squibb spokesperson. The combination pill would include Bristol-Myers Squibb's Sustiva and Gilead's Viread and Emtriva, according to the AP/Chronicle (Johnson, AP/Houston Chronicle, 12/20). Gilead, since it will provide two of the three drugs, will assume 67% of the costs and receive 67% of the revenue, the San Jose Mercury News reports. The current wholesale price of the three drugs sold separately is about $35 a day. However, the companies have not stated the projected cost of the combination antiretroviral drug if it is approved for sale in the United States, according to the Mercury News (Jacobs, San Jose Mercury News, 12/21). The companies first will seek approval in the United States and then in Europe and Canada, according to the AP/Chronicle. A single dose pill would make it "much easier" for HIV/AIDS patients to keep up with their medication, according to the AP/Chronicle. Currently, antiretroviral treatment requires patients to take several pills a day, sometimes at specific times and under certain conditions, making it "extremely difficult" to abide by the "complex schedule," according to the AP/Chronicle (AP/Houston Chronicle, 12/20).
Reports Examine HIV/AIDS Issues in Myanmar; Global HIV/AIDS Awareness; AIDS Orphans in Africa; World AIDS Day 2004 News Coverage
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.